- Home
- PNI vs CRDF Comparison
PNI vs CRDF Comparison
Compare PNI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | CRDF |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.8M | 86.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | PNI | CRDF |
|---|---|---|
| Price | $6.83 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 46.5K | ★ 781.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $6.54 | $0.76 |
| 52 Week High | $7.20 | $3.31 |
Technical Indicators
Market Signals| Indicator | PNI | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 37.16 | 45.62 |
| Support Level | $6.64 | $0.76 |
| Resistance Level | $7.07 | $1.13 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.11 | 25.86 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.